Inactive Instrument

Bone Biologics Corporation Stock Other OTC

Equities

BBLG

US0980702049

Medical Equipment, Supplies & Distribution

Sales 2024 * - Sales 2025 * - Capitalization 1.41M
Net income 2024 * -8M Net income 2025 * -8M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.05 x
P/E ratio 2025 *
-0.05 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.85%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 59 15-08-16
Director of Finance/CFO 60 14-10-31
Members of the board TitleAgeSince
Director/Board Member 75 11-12-31
Chairman 81 18-07-15
Director/Board Member 49 Jan. 07
More insiders
Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
More about the company